CoChat
Sign Up
Cited by 54Toxoplasma gondii Research Studiesvaccines and immunoinformatics approachesImmunotherapy and Immune Responses

The DOI matches its Crossref record.

Characterization of a multi-epitope peptide with selective MHC-binding capabilities encapsulated in PLGA nanoparticles as a novel vaccine candidate against Toxoplasma gondii infection

Roozbehani, Mona, Falak, Reza, Mohammadi, Mohsen, Hemphill, Andrew, Razmjou, Elham, Meamar, Ahmad reza, Masoori, Leila, Khoshmirsafa, Majid, Moradi, Maryam, Gharavi, Mohammad Javad·2018·Vaccine
DOI 10.1016/j.vaccine.2018.08.068
Open this paper in CoChat — free account

Abstract

No effective human vaccine against Toxoplasma gondii (T. gondii) has yet been developed; however, a protective vaccine using immunogenic peptides in a safe delivery vehicle system offers promise. Here, we employed bioinformatics to design a multimeric recombinant T. gondii vaccine using predicted T and B cell epitopes of SAG1, AMA1, ROP2, and GRA4 proteins based on their binding capabilities to common major histocompatibility complex (MHC) molecules. Furthermore, we encapsulated the expressed protein in poly lactic-co-glycolic acid (PLGA) nanoparticles as a delivery vehicle and also used alum as an adjuvant to determine the vaccine potency of this multimeric antigen. BALB/c mice were vaccinated and then challenged with T. gondii RH strain, and the survival rate and cytokine profiles were studied. Mice vaccinated with the multi-epitope-based vaccine, both with and without PLGA, had greater Th1 immune responses, survival rates, specific antibody titers, and IFN-γ and IL-2 levels than controls, while the alum-adsorbed vaccine stimulated a Th2-type humoral immune response.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.vaccine.2018.08.068

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 45

  1. Blader, 2015, Lytic cycle of T. gondii: 15 years later, Annu Rev Microbiol, 69, 463, 10.1146/annurev-micro-091014-104100 · DOI
  2. Gharavi, 2017, Detection of anti-T. gondii antibodies in chronic myeloid leukemia and acute myeloid leukemia patients, Vet World, 10, 1063, 10.14202/vetworld.2017.1063-1065 · DOI
  3. Tan, 2010, Identification of T. gondii epitopes, adjuvants, and host genetic factors that influence protection of mice and humans, Vaccine, 28, 3977, 10.1016/j.vaccine.2010.03.028 · DOI
  4. Neville, 2015, Clinically available medicines demonstrating anti-Toxoplasma activity, Antimicrob Agents Chemother, 59, 7161, 10.1128/AAC.02009-15 · DOI
  5. Grover, 2012, The Toxoplasma gondii peptide AS15 elicits CD4 T cells that can control parasite burden, Infect Immun, 80, 3279e88, 10.1128/IAI.00425-12 · DOI
  6. Bhopale, 2003, Development of a vaccine for toxoplasmosis: current status, Microbes Infect, 5, 457, 10.1016/S1286-4579(03)00048-0 · DOI
  7. Wang, 2011, Increased survival time in mice vaccinated with a branched lysine multiple antigenic peptide containing B-and T-cell epitopes from T. gondii antigens, Vaccine, 29, 8619, 10.1016/j.vaccine.2011.09.016 · DOI
  8. Santos, 2011, Intramembrane cleavage of AMA1 triggers toxoplasma to switch from an invasive to a replicative mode, Science, 331, 473, 10.1126/science.1199284 · DOI
  9. Dlugonska, 2008, Toxoplasma rhoptries: unique secretory organelles and source of promising vaccine proteins for immunoprevention of toxoplasmosis, J Biomed Biotechnol, 2008, 632424, 10.1155/2008/632424 · DOI
  10. Mercier, 2015, Toxoplasma secretory granules: one population or more?, Trends Parasitol, 31, 60, 10.1016/j.pt.2014.12.002 · DOI
  11. Dziadek, 2012, Recombinant ROP2, ROP4, GRA4 and SAG1 antigen-cocktails as possible tools for immunoprophylaxis of toxoplasmosis: what’s next?, Bioengineered, 3, 358, 10.4161/bioe.21541 · DOI
  12. Garcia, 2014, Current progress toward vaccines against T. gondii, Vaccine Devel Ther, 4, 23, 10.2147/VDT.S57474 · DOI
  13. Sánchez, 2011, Combination of CpG-oligodeoxynucleotides with recombinant ROP2 or GRA4 proteins induces protective immunity against T. gondii infection, Exp Parasitol, 128, 448, 10.1016/j.exppara.2011.04.004 · DOI
  14. Allahyari, 2016, Peptide/protein vaccine delivery system based on PLGA particles, Hum Vaccin Immunother, 12, 806, 10.1080/21645515.2015.1102804 · DOI
  15. Ahmadpour, 2017, Enhancing immune responses to a DNA vaccine encoding T. gondii GRA14 by calcium phosphate nanoparticles as an adjuvant, Immunol Lett, 185, 40, 10.1016/j.imlet.2017.03.006 · DOI
  16. Grzybowski, 2015, Towards vaccine against toxoplasmosis: evaluation of the immunogenic and protective activity of recombinant ROP5 and ROP18 T. gondii proteins, Parasitol Res, 114, 4553, 10.1007/s00436-015-4701-y · DOI
  17. Zhao, 2013, Advances in the study of HLA-restricted epitope vaccines, Hum Vaccin Immunother, 9, 2566, 10.4161/hv.26088 · DOI
  18. Graille, 2005, Crystal structure of the complex between the monomeric form of T. gondii surface antigen 1 (SAG1) and a monoclonal antibody that mimics the human immune response, J Mol Biol, 354, 447, 10.1016/j.jmb.2005.09.028 · DOI
  19. Mokhtarian, 2016, Serodiagnosis of fasciolosis by fast protein liquid chromatography-fractionated excretory/secretory antigens, Parasitol Res, 115, 2957, 10.1007/s00436-016-5049-7 · DOI
  20. Salari, 2015, Down-regulation of Th2 immune responses by sublingual administration of poly (lactic-co-glycolic) acid (PLGA)-encapsulated allergen in BALB/c mice, Int Immunopharmacol, 29, 672, 10.1016/j.intimp.2015.09.011 · DOI
  21. Naseri, 2016, Scolicidal and apoptotic activities of albendazole sulfoxide and albendazole sulfoxide-loaded PLGA-PEG as a novel nanopolymeric particle against Echinococcus granulosus protoscoleces, Parasitol Res, 115, 4595, 10.1007/s00436-016-5250-8 · DOI
  22. Pawar, 2013, Development and characterization of surface modified PLGA nanoparticles for nasal vaccine delivery: effect of mucoadhesive coating on antigen uptake and immune adjuvant activity, Eur J Pharm Biopharm, 85, 550, 10.1016/j.ejpb.2013.06.017 · DOI
  23. Li, 2011, Comparative evaluation of immunization with recombinant protein and plasmid DNA vaccines of fusion antigen ROP2 and SAG1 from T. gondii in mice: cellular and humoral immune responses, Parasitol Res, 109, 637, 10.1007/s00436-011-2296-5 · DOI
  24. Ahmadpour, 2017, Evaluation of the immune response in BALB/c mice induced by a novel DNA vaccine expressing GRA14 against T. gondii, Parasite Immunol, 39, 1, 10.1111/pim.12419 · DOI
  25. Suhrbier, 1997, Multi-epitope DNA vaccines, Immunol Cell Biol, 75, 402, 10.1038/icb.1997.63 · DOI
  26. Cong, 2011, Towards an immunosense vaccine to prevent toxoplasmosis: protective T. gondii epitopes restricted by HLA-A*0201, Vaccine, 29, 754, 10.1016/j.vaccine.2010.11.015 · DOI
  27. Huang, 2016, In silico and in vivo analysis of T. gondii epitopes by correlating survival data with peptide-MHC-I binding affinities, IJID, 48, 14
  28. Cong, 2012, T. gondii HLA-B*0702-restricted GRA7(20–28) peptide with adjuvants and a universal helper T cell epitope elicits CD8(+) T cells producing interferon-gamma and reduces parasite burden in HLA-B*0702 mice, Hum Immunol, 73, 1, 10.1016/j.humimm.2011.10.006 · DOI
  29. El Bissati, 2016, Adjuvanted multi-epitope vaccines protect HLA-A* 11: 01 transgenic mice against T. gondii, JCI Insight, 1, 85955, 10.1172/jci.insight.85955 · DOI
  30. Jongert, 2009, Vaccines against T. gondii: challenges and opportunities, Mem Inst Oswaldo Cruz, 104, 252, 10.1590/S0074-02762009000200019 · DOI · Paper page
  31. Lim, 2014, Recent advances in T. gondii immunotherapeutics, Korean J Parasitol, 52, 581, 10.3347/kjp.2014.52.6.581 · DOI
  32. Skwarczynski, 2016, Peptide-based synthetic vaccines, Chem Sci, 7, 842, 10.1039/C5SC03892H · DOI · Paper page
  33. Cao, 2015, Vaccination with a DNA vaccine encoding T-and B-cell epitopes of SAG1, GRA2, GRA7 and ROP16 elicits protection against acute toxoplasmosis in mice, Vaccine, 33, 6757, 10.1016/j.vaccine.2015.10.077 · DOI
  34. Xu, 2014, Evaluation of immuno-efficacy of a novel DNA vaccine encoding T. gondii rhoptry protein 38 (TgROP38) against chronic toxoplasmosis in a murine model, BMC Infect Dis, 14, 525, 10.1186/1471-2334-14-525 · DOI
  35. Miceli, 1991, The roles of CD4 and CD8 in T cell activation, Semin Immunol, 3, 133
  36. Bhadra, 2011, The CD8 T-cell road to immunotherapy of toxoplasmosis, Immunotherapy, 3, 789, 10.2217/imt.11.68 · DOI
  37. Alving, 2012, Adjuvants for human vaccines, Curr Opin Immunol, 24, 310, 10.1016/j.coi.2012.03.008 · DOI
  38. Singh, 2003, Recent advances in veterinary vaccine adjuvants, Int J Parasitol, 33, 469, 10.1016/S0020-7519(03)00053-5 · DOI
  39. Petersen, 1998, Immunization with E. coli produced recombinant T. gondii SAG1 with alum as adjuvant protect mice against lethal infection with T. gondii, Vaccine, 16, 1283, 10.1016/S0264-410X(98)00039-5 · DOI
  40. Song, 2017, Vaccination with toxofilin DNA in combination with an alum-monophosphoryl lipid A mixed adjuvant induces significant protective immunity against T. gondii, BMC Infect Dis, 17, 19, 10.1186/s12879-016-2147-1 · DOI
  41. Martin, 2004, Recombinant GRA4 or ROP2 protein combined with alum or the gra4 gene provides partial protection in chronic murine models of toxoplasmosis, Clin Diagn Lab Immunol, 1, 704, 10.1128/CDLI.11.4.704-710.2004 · DOI
  42. Zhang, 2016, Vaccination with T. gondii calcium-dependent protein kinase 6 and rhoptry protein 18 encapsulated in poly(lactide-co-glycolide) microspheres induces long-term protective immunity in mice, BMC Infect Dis, 16, 168, 10.1186/s12879-016-1496-0 · DOI
  43. Chuang, 2013, Encapsulation of chimeric protein rSAG1/2 into poly(lactide-co-glycolide) microparticles induces long-term protective immunity against T. gondii in mice, Exp Parasitol, 134, 430, 10.1016/j.exppara.2013.04.002 · DOI
  44. Nabi, 2017, Induction of specific humoral immune response in mice immunized with ROP18 nanospheres from T. gondii, Parasitol Res, 116, 359, 10.1007/s00436-016-5298-5 · DOI
  45. Allahyari, 2016, Synergistic effect of rSAG1 and rGRA2 antigens formulated in PLGA microspheres in eliciting immune protection against Toxoplasama gondii, Exp Parasitol, 170, 236, 10.1016/j.exppara.2016.09.008 · DOI

Cited by

Sorted by citations

Metadata

Authors
Roozbehani, M., Falak, R., Mohammadi, M., Hemphill, A., Razmjou, E., Meamar, A. R., Masoori, L., Khoshmirsafa, M., Moradi, M., & Gharavi, M. J.
Affiliations
  • Iran University of Medical Sciences (IR)
  • Bushehr University of Medical Sciences (IR)
  • University of Bern (CH)
Corresponding author
  • Razmjou, Elham
  • Gharavi, Mohammad Javad
ORCID
Venue
Vaccine
Publisher
Elsevier BV
Published
2018-10
Volume
36
Issue
41
Pages
6124-6132
ISSN
0264-410X (ISSN-L)
DOI
10.1016/j.vaccine.2018.08.068
OpenAlex
W2888923518
Cited by
54
References
0
Citations by year
2026: 1 · 2025: 4 · 2024: 9 · 2023: 4 · 2022: 5 · 2021: 16 · 2020: 9 · 2019: 6
FWCI
6.26
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Vaccine (publishedVersion)
  • PubMed (publishedVersion)
  • BORIS (University Library Bern) (submittedVersion)
Funders
Iran University of Medical Sciences (9221577201)
Topics
  • Life Sciences › Immunology and Microbiology › Parasitology › Toxoplasma gondii Research Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
Toxoplasma gondii, toxoplasmosis vaccine, multi-epitope peptide, MHC-binding peptides, PLGA nanoparticles, vaccine delivery, SAG1, AMA1, ROP2, T cell epitopes, B-cell epitopes, alum adjuvant, Th1 response, interferon-gamma, interleukin-2, cytokine profile
MeSH terms
Polylactic Acid-Polyglycolic Acid Copolymer, Adjuvants, Immunologic, Animals, Antibodies, Protozoan, Antigens, Protozoan, Female, Interferon-gamma, Interleukin-2, Mice, Inbred BALB C, Peptides, Toxoplasma, Protozoan Proteins, Protozoan Vaccines, Computational Biology, Mice, Nanoparticles, Immunity, Humoral

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review